Leukemia Therapeutics Market Research Report: by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) - Forecast Till 2030

Leukemia Therapeutics Market Overview

The market will hold a CAGR of 7.50% and a value of USD 26 881.88 million by 2030. The market will have high growth in the coming years if the market grows at the same pace. Cancer is a disease of genes caused by the uncontrolled growth of the cells in the body. The affected cells can further spread into another body site from that part through the blood and lymph system. It is known as blood cancer which commonly can happen to adults or children. Several types of leukemia are there, and leukemia therapeutics are used to treat them. The factors that improve the market are the rise of the older population, lifestyle changes, and others are some of the major causes of the market growth. However, the constraint that also hampers the growth pace is the high cost needed to develop new therapeutics. It makes an individual weak and loses the ability to fight any infection. The awareness among people regarding cancer disease and the sudden availability of detection and diagnosis will create more opportunities for the market. Common symptoms of this disease are fatigue, weight loss, frequent infections, easy bleeding or bruising, and some others.

Leukemia Therapeutics Market Segmentation

The global leukemia therapeutics market has been segmented into type, applications, and region.

Based on type, market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.

Based on applications, market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.

The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.

Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to increase prevalence of leukemia.

The market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the leukemia therapeutics market.

Market of Leukemia Therapeutics, by Treatment Type

• Chemotherapy




• Alkylating Agents


• Antimetabolites


• Antitumor Antibiotics


• Others




• Biological Therapy


• Targeted Therapy


• Radiation Therapy


• Stem Cell Transplant


• Others

Market of Leukemia Therapeutics, by Application

• Acute Lymphocytic Leukemia


• Acute Myelogenous Leukemia


• Chronic Lymphocytic Leukemia


• Chronic Myelogenous Leukemia


• Others

Market of Leukemia Therapeutics, by Region

• Americas




• North America




• US


• Canada




• Latin America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Market of Leukemia Therapeutics, by Key Players

• Eisai Co., Ltd (Japan)


• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Bristol-Myers Squibb Company (US)


• Hoffmann-La Roche AG (Switzerland)


• Sanofi S.A. (France)


• Teva Pharmaceutical Industries Ltd (Israel)


• Amgen Inc (US)


• Takeda Pharmaceutical Company Ltd (Japan)

Recent Development

May 2022

BeiGene is a worldwide science-driven biotechnology company that focuses on developing innovative and affordable medicines to improve treatment. It outcomes and access for patients worldwide. The company recently announced that the China National Medical Products Administration (NMPA) had granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. The NMPA gave conditional approval for adult patients in this indication in December 2020.

April 2022

Curis, Inc., a biotechnology company, focuses on developing innovative therapeutics to treat cancer. Intended Audience

• Leukemia Therapeutics Manufacturers and Vendors


• Research Organization


• Various Research and Consulting Firms


• Cancer Organization and Association